Metrifonate in the control of urinary schistosomiasis in Zanzibar

Selective population chemotherapy using three doses of metrifonate (7.5 mg/kg body weight each time) at two-week intervals was assessed in an entire community in Kinyasini district in Zanzibar, United Republic of Tanzania. The objectives of the study were to (1) reduce the prevalence of heavy infections (defined as greater than or equal to 50 S. haematobium eggs per 10 ml of urine) by 75% in two years, and (2) reduce the overall prevalence of infection by 50% in two years. A total of 4113 people were examined at least once during the two-year period. In the initial survey the highest proportion of infected individuals was in the 10-14-year age group, and in all subsequent surveys in the 5-9-year age group. The age group with the highest proportion of heavily infected individuals was 5-9 years for all surveys. The overall reduction of prevalence of infection from survey 1 to survey 4 was 52.9% and the prevalence of heavy infection was reduced by 62.2%. The conversion rates (negative to positive in two consecutive surveys) were highest in the longest interval of 12 months and the rates of reversion (positive to negative in two consecutive surveys, without a history of treatment) were highest in the shortest interval of 4 months. Some statistically significant relationships were observed between the number of doses and the egg reduction rates. However, for the egg-negative rates, no statistically significant relationship was observed. In the 4-month interval a 67.6% egg-negative rate was observed among those who took at least one dose; with the 12-month interval a 48.3% egg-negative rate was observed. Thus, selective population chemotherapy with metrifonate was shown to reduce the prevalence and intensity of infection due to S. haematobium over a 24-month period.